The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Reckitt Benckiser Group plc (“Reckitt” or “the Company”) (OTC: RBGLY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Reckitt and its senior executives developed a scheme to mislead both investors and the public about its Suboxone Film product, including health and safety risks. This scheme also facilitated the abuse of opiates by U.S. consumers. As part of the scheme, Reckitt touted the safety of the Suboxone Film product while falsely constructing safety concerns about traditional Suboxone tablets. Reckitt’s scheme enriched the company by more than $3 billion, but eventually resulted in investigations by both the DOJ and the FTC. Reckitt settled the investigations into Suboxone Film for $1.4 billion in what was called the “largest opioid settlement in US history.” Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Reckitt, investors suffered damages.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190913005373/en/